TNFSF10 and infection: None of these transient lymphocytopaenias were associated with clinically relevant infections, but subsequent studies of mapatumumab should evaluate this further, for example, by characterising lymphocyte subsets in patients who experience lymphocytopaenia, especially as TRAIL targets certain lymphocyte subsets (Janssen et al, 2005).